Chris Lau

Chris Lau

InvestorPlace Contributor

Expertise: Technology, Biotech

Expertise:

Technology
Biotech

Education:

Bachelor of Science
Project Management Professional

Awards and Accomplishments:

Top 100 Tipranks 2015-2021

About Chris:

Chris has over two decades of investing experience. He is an Honors B.Sc graduate (with distinction) in Science and Economics. He holds a Project Management Professional designation

Chris focuses on the technology, cyclical, and healthcare sector. He runs a newsletter with speculative Triple-baggers.

His investment strategy is based on finding undervalued stocks trading at a steep discount to their intrinsic value.

Follow Chris on DIY Value Investing.

Recent Articles

Why Groupon Inc (GRPN) Stock Is Ready for a Comeback

By Chris Lau, InvestorPlace Contributor

When Groupon reports fourth-quarter results, GRPN stock could rally if it reports that seasonal strength is once again boosting revenue.

Is Micron Technology, Inc. (MU) Stock Really Worth $35?

By Chris Lau, InvestorPlace Contributor

MU stock's upgrade is late, but shares are worth at least $30 a share. Micron stock is worth even more if the memory super-cycle plays out.

Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Stock: Will the Slump End?

By Chris Lau, InvestorPlace Contributor

The flood of Teva Pharmaceutical's (TEVA) bad news, such as a CEO departure and patent case loses, just keep pummeling TEVA stock.

Why Advanced Micro Devices, Inc. (AMD) Stock Will Hit $15 Soon

By Chris Lau, InvestorPlace Contributor

Advanced Micro Devices is just one month away from launching Ryzen. When it does, AMD stock may breakout to new highs and past $15 a share.

BlackBerry Ltd (BBRY) Stock Worth $8 a Share

By Chris Lau, InvestorPlace Contributor

BlackBerry is releasing a BBM software development kit. This is a necessary step as BBRY stock moves toward being more of a software company.

Next Stop for Nokia Corp (ADR) Stock: $5 a Share!

By Chris Lau, InvestorPlace Contributor

Nokia (NOK) reported a solid quarter, but investors ignored the potential for more IP and brand revenue and network demand rebounding.

Watch User Engagement When Twitter Inc (TWTR) Stock Reports Earnings

By Chris Lau, InvestorPlace Contributor

Twitter (TWTR) is either a buyout target or fairly valued and moving nowhere. The earnings report on Feb 9 may give the stock a lift.

3 Beaten Biotech Stocks That Are Set to Rebound

By Chris Lau, InvestorPlace Contributor

Horizon Pharma (HZNP), Synergy Pharmaceuticals (SGYP) and Keryx Biopharmaceuticals (KERX) are down sharply, but are set to rebound.

Why Valeant Pharmaceuticals Intl Inc (VRX) Stock Will Finally Stabilize

By Chris Lau, InvestorPlace Contributor

Valeant Pharmaceuticals (VRX) is finally getting its house in order. Don't expect VRX stock to explode, but it will get a lift.

Twitter Inc (TWTR) Sells Fabric, So Where Is the Takeover Offer?

By Chris Lau, InvestorPlace Contributor

Twitter (TWTR) looked ripe for getting bought out last year, so after selling Fabric to Alphabet, when is the bid for TWTR stock coming?

Load More